Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy.

• Authors: Mehmet Asim Bilen, Emory University; Dylan J. Martini, Emory University; Yuan Liu, Emory University; Julie M. Shabto, Emory University; Jacqueline T. Brown, Emory University; Milton Williams, Emory University; Amir I. Khan, Emory University; Alexandra Speak, Emory University; Colleen Lewis, Emory University; Hannah Collins, Emory University; Haydn Thomas Kissick, Emory University; Bradley Carthon, Emory University; Mehmet Akce, Emory University; Walid Shaib, Emory University; Olatunji Alese, Emory University; Rathi Pillai, Emory University; Conor Ermst Steuer, Emory University; Christina S. Wu, Emory University; David H Lawson, Emory University; Ragini R. Kudchadkar, Emory University; Bassel El-Rayes, Emory University; Suresh S Ramalingam, Emory University; Taofeek K Owonikoko, Emory University; R Donald Harvey, Emory University; Viraj Master, Emory University
• Journal Title: Oncologist
• Volume: Volume 25, Number 3
• Publisher: AlphaMed Press: Oncologist | 2020-03, Pages e528-e535
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1634/theoncologist.2019-0751
• Subjects: Health Sciences, Immunology
• Keywords: Biomarkers; Immunotherapy; Inflammation; Risk stratification; Sarcopenia

Abstract

BACKGROUND: Sarcopenia and inflammation have been associated with poor survival in patients with cancer. We explored the combined effects of these variables on survival in patients with cancer treated with immunotherapy. METHODS: We performed a retrospective review of 90 patients enrolled on immunotherapy-based phase I clinical trials at Emory University from 2009 to 2017. Baseline neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio (PLR) were used as surrogates of inflammation. The skeletal muscle index (SMI) was derived from the skeletal muscle density calculated from baseline abdominal computed tomography images. Optimal cutoffs for continuous inflammation biomarkers and SMI were determined by bias-adjusted log-rank test. A four-level risk stratification was used to create low-risk (PLR <242 and nonsarcopenic), intermediate-risk (PLR <242 and sarcopenic), high-risk (PLR ≥242 and nonsarcopenic), and very-high-risk (PLR ≥242 and sarcopenic) groups with subsequent association with survival. RESULTS: Most patients (59%) were male, and the most common cancers were melanoma (33%) and gastrointestinal (22%). Very high-risk, high-risk, and intermediate-risk patients had significantly shorter overall survival (hazard ratio [HR], 8.46; 95% confidence interval [CI], 2.65-27.01; p < .001; HR, 5.32; CI, 1.96-14.43; p = .001; and HR, 4.01; CI, 1.66-9.68; p = .002, respectively) and progression-free survival (HR, 12.29; CI, 5.15-29.32; p < .001; HR, 3.51; CI, 1.37-9.02; p = .009; and HR, 2.14; CI, 1.12-4.10; p = .022, respectively) compared with low-risk patients. CONCLUSION: Baseline sarcopenia and elevated inflammatory biomarkers may have a combined effect on decreasing survival in immunotherapy-treated patients in phase I trials. These data may be immediately applicable for medical oncologists for the risk stratification of patients beginning immunotherapeutic agents. IMPLICATIONS FOR PRACTICE: Sarcopenia and inflammation have been associated with poor survival in patients with cancer, but it is unclear how to apply this information to patient care. The authors created a risk-stratification system that combined sarcopenia and platelet-to-lymphocyte ratio as a marker of systemic inflammation. The presence of sarcopenia and systemic inflammation decreased progression-free survival and overall survival in our cohort of 90 patients who received immunotherapy in phase I clinical trials. The data presented in this study may be immediately applicable for medical oncologists as a way to risk-stratify patients who are beginning treatment with immunotherapy.